Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Disability and HIV: Vulnerability of People With Disabilities to HIV Infection in Sub-Saharan Africa (HandiVIH)

11 juillet 2016 mis à jour par: ANRS, Emerging Infectious Diseases

Disability and HIV: an Appraisal of the Vulnerability of People With Disabilities to HIV Infection in Two Main Cities of Sub-Saharan Africa

According to the recent World Report on Disability, around 15% of the world population lives with a disability and 80% of people with disabilities (PWD) live in developing countries. More and more evidence show that PWD are more likely to be poor, vulnerable to physical and sexual violence, and to have less access to education. Therefore, PWD are likely to have an increased risk for HIV infection, potentially being a key population in regard to this epidemic.

The vulnerability of PWD was recognized in 2007 by the United Nations Convention on the Rights of Persons with Disabilities. However, data on the extent how PWD are affected by HIV is still very limited. As a result, PWD are usually overlooked by National AIDS Control Programmes and few projects specifically targeting them have been developed.

Recognizing the need for appropriate and reliable data to help protect the rights of PWD and achieve a better inclusion of disability in National AIDS Control Programmes, the Institute of Research for Development (IRD), the Institut de Formation et Recherche Demographique (IFORD) and Handicap International (HI) propose this study that aims to provide quantitative and qualitative data on the vulnerability of PWD to HIV infection in Cameroon and Burkina Faso, in order to define if this vulnerable population is also a Key Population in relation to the HIV epidemic. This study adopts a multidisciplinary approach (quantitative and qualitative methods). Quantitative data are collected only in Cameroon.

Only the quantitative study is described here.

Aperçu de l'étude

Statut

Complété

Les conditions

Description détaillée

OBJECTIVES:

The general objective of this study is to provide information on the vulnerability of PWD to HIV infection.

The objectives of the quantitative component of this study are:

Estimation of the HIV burden among PWD:

  • To estimate the prevalence of HIV in PWD comprehensively and for each of the following disabilities 1) hearing 2) visual 3) mobility 4) cognitive (intellectual)
  • To compare the HIV prevalence between PWD and non-disabled matched controls
  • To assess the association between PWD's social network characteristics and the risk for HIV

Assessment of the knowledge, behaviour and practice toward HIV infection and sexual and reproductive health (including contraception) overall and for each of the impairment groups mentioned above:

  • To describe and analyze the knowledge, attitude and behaviours related to HIV infection
  • To compare the knowledge, attitude and behaviours between PWD and non-disabled matched controls
  • To describe sexual and reproductive activities of PWD
  • To describe and analyze the access and actual use of family planning methods in PWD

Access to HIV prevention and health careglobally and for each of the impairment groups mentioned above:

  • To describe and analyze the determinants of and barriers to access to prevention and testing services
  • To describe and analyze the determinants of and barriers to access to care
  • To compare the access to services between PWD and non-disabled matched controls

Specific objectives related to disability:

  • To describe the population of PWD in Yaoundé
  • To describe and analyze the characteristics of the social networks of PWD

METHODOLOGY

Study design:

This is a cross sectionnal study assessing HIV prevalence, HIV risk factors and sexual & reproductive health of PWD compared to a control group of Non-Disabled People. PWD are sampled from the general population using a two-step sampling method. Eligible subjects are proposed an HIV test and to respond to a questionnaire on their Knowledge, Attitudes and Practices (KAP) in relation to HIV and SRH, on their social network and on their access to prevention and care services. The life-grid interview method is used to collect data on subject's history of social participation, employment, resources, sexual partnership and reproductive life. Controls are selected from the PWD's neighborhood.

Sample size:

850 disabled subjects and 850 non-disabled controls

Study location: Yaounde, Cameroon

Estimated planning or Study timetable :

Study start date: April 2014 (exploratory work) Total trial/study duration: 24 months

Type d'étude

Observationnel

Inscription (Réel)

1610

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

15 ans à 49 ans (Enfant, Adulte)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

Community sample:

- PWD are identified thanks to the disability screening tool developped by the Washington Group (WG). This tool is based on the WHO International Classification of Functionning (ICF).

A stratified cluster sampling in 2 steps is used in Yaounde. The city has been divided in enumeration areas (EAs). First step : EAs are drawn randomly with probability proportional to their size in number of households. Second step: in each EA, 30 households are randomly drawn and each person living in these households is screened for disability with the WG tool, according to the inclusion and exclusion criteria.

- For each PWD, 1 non-disabled control person is randomly chosen from the census list of the same enumeration area. Controls are matched on age and sex.

La description

For PWD:

Inclusion Criteria:

  • Age 15 to 49 years
  • WG criteria: ≥ 1 major impairment or 2 minor difficulties with an activity
  • Informed consent given

Exclusion Criteria:

  • Any severe disease that, according to the investigator, precludes the participation of the subject to ANY aspect of the study
  • Temporary impairment (>1 year) which is likely to be cured quickly
  • Subject consenting to none of the aspects of the study.

For Non-Disabled People (control group):

Inclusion criteria:

  • Age 15 to 45 years in an interval of 5 years compared to the index PWD;
  • Same sex as the index PWD;
  • Not answering to the WG criteria for disability;
  • Living in the same enumeration area as the Index PWD;
  • Informed consent given.

Exclusion criteria:

  • Any conditions, that - according to the interviewer - don't permit to participate at any part of the study;
  • Subject consenting to none of the aspects of the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

Cohortes et interventions

Groupe / Cohorte
People with Disability (PWD) (N= 850)

PWD will be identified thanks to the disability screening tool developped by the Washington Group (WG). This tool is based on the WHO International Classification of Functionning (ICF).

A stratified cluster sampling in 2 steps will be used in both, Yaounde and Ouagadougou. Each city will be divided in enumeration areas (EAs). First step : EAs will be drawn randomly with probability proportional to their size in number of households. Second step: in each EA, 30 households will be randomly drawn and each person living in these households will be screened for disability with the WG tool, according to the inclusion and exclusion criteria.
Non-Disabled People (control group) (N= 850)
For each PWD, 1 non-disabled control person will be randomly chosen from the census list of the same enumeration area. Control will also be matched on age and sex.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
HIV prevalence
Délai: 10 months
HIV prevalence among People With Disability compared to Non-Disabled People. HIV serology will be assessed by rapid diagnostic tests.
10 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Risk factors
Délai: 10 months
Risk factors to HIV and reproductive health behaviours among People with Disability compared to Non-Disabled People. Different risk factors (Knowledges - Attitudes - Practices) for HIV and reproductive health behaviours will be assessed in both groups, the people with disability group and the control non-disabled people group, through a questionnaire.
10 months

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Access to care
Délai: 10 months
Access to services among People with Disability compared to Non-Disabled People. Access to reproductive health and HIV services will be assessed in both groups, through a questionnaire.
10 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

ANRS, Emerging Infectious Diseases

Collaborateurs

Institut de Recherche pour le Developpement
Handicap International
Institut de Formation et de Recherche Démographique
Forum Camerounais de Psychologie
Centre de Recherche Internationale pour la Santé de l'Université de Ouagadougou

Les enquêteurs

  • Directeur d'études: Pierre DE BEAUDRAP, MD, PhD, Institut de Recherche pour le Développement (IRD)
  • Directeur d'études: Gervais BENINGISSE, PhD, Institut de Formation et Recherche Demographique (IFORD)

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 novembre 2014

Achèvement primaire (Réel)

1 décembre 2015

Achèvement de l'étude (Réel)

1 juillet 2016

Dates d'inscription aux études

Première soumission

11 juillet 2014

Première soumission répondant aux critères de contrôle qualité

16 juillet 2014

Première publication (Estimation)

17 juillet 2014

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

12 juillet 2016

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 juillet 2016

Dernière vérification

1 juillet 2016

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • ANRS 12302 - HandiVIH

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur VIH

Rechercher des essais similaires

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

CROs by country

CROs in Poland

Conditions

Maladies rares

Interventions en matière de drogue

Compléments alimentaires

Commanditaire / collaborateurs

Emplacements

3
S'abonner